The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs

Biotech stocks came under pressure in the week ended Aug. 14 amid mixed earnings news flow from the sector. FDA decisions scheduled for the week also produced adverse outcomes. Eagle Pharmaceuticals Inc EGRX and Fennec Pharmaceuticals Inc FENC received complete response letters for their respective regulatory applications, while a decision on Eton Pharmaceuticals Inc's ETON eye inflammation drug hadn't come by the Aug. 10 decision date.

The week, however, saw a signing spree by coronavirus vaccine developers, which stitched up manufacturing as well as supply deals.

Here are the key catalysts for the unfolding week.

Conferences

Virtual Keystone Symposia: Advances in Cancer Immunotherapy: Aug. 17-19

PDUFA Dates

Gilead Sciences, Inc. GILD and licensing partner GALAPAGOS NV/S ADR GLPG await FDA decision on the NDA for filgotinib in moderate-to-severe rheumatoid arthritis. (estimated date of Wednesday, Aug. 19, assuming priority review)

The FDA is set to rule on BioMarin Pharmaceutical Inc.'s BMRN BLA for valoctocogene roxaparvovec, its investigational AAV5 gene therapy for treating adults with hemophilia A. (Friday)

Tricida Inc TCDA has a Aug. 22 PDUFA date for the NDA for its TRC 101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease. With FDA's communication to the company in mid-July, stating that it has identified deficiencies in the application, it is less likely the investigational drug is approved by the D-day. (Saturday)

See also: Genoskin Offers Live Skin Models To Bridge Animal, Human Testing: 'The Market Opportunity Is Huge'

Earnings

Monday

Milestone Scientific Inc. MLSS (before the market open)
China Biologic Products Holdings Inc CBPO (after the close)
Precipio Inc PRPO (after the close)

Tuesday

ADC Therapeutics SA ADCT (before the market open)
PAVmed Inc PAVM (after the close)
Supernus Pharmaceuticals Inc SUPN (after the close)

IPOs

La Jolla, California-based InhibRx, a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, with particular focus on oncology, has filed with the SEC to offer 6 million shares of its common stock at an estimated price range of $16-$18. The company said in the filing it has applied to list its shares on the Nasdaq under the ticker symbol INBX.

Harmony Biosciences Holdings Inc, a Plymouth, Pennsylvania-based commercial-stage pharmaceutical company focused on innovative therapies for patients living with rare neurological disorders, has filed with the SEC to offer 4.651 million shares of its common stock. The estimated price range for the offering is $20-$23. The company has applied for listing its shares on the Nasdaq under the ticker symbol HRMY.

IPO Quiet Period Expiry

Nurix Therapeutics Inc NRIX
iTeos Therapeutics Inc ITOS
Inozyme Pharma Inc INZY
Annexon Inc ANNX

Related Link: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

Posted In: GileadBiotechEarningsNewsPenny StocksHealth CarePreviewsFDAIPOsTop StoriesTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.